secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeoVax Labs, Inc. (GOVX)
CIK:        0000832489
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001437749-23-031145
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeoVax Q3 net loss widens to $8.4M; Phase 2 COVID vaccine enrollment completed
------------------------------------------------------------------------------

- Net loss $8.4M ($0.32/share) vs $3.97M ($0.17/share) in Q3 2022; cash $12.7M at Sep 30 vs $27.6M at Dec 31.
- R&D expenses rose to $6.9M from $2.7M, driven by clinical trial costs for GEO-CM04S1 and Gedeptin.
- Completed enrollment in Phase 2 trial of GEO-CM04S1 as a booster; initial data readout expected soon.
- Signed multi-product license with ProBioGen for AGE1.CR.pIX suspension cell line to enhance MVA vaccine manufacturing.
- Received U.S. patent allowances for Ebola, Marburg, Malaria, and HIV vaccines.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/832489/000143774923031145/0001437749-23-031145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/832489/000143774923031145/govx20231108_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-031145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer